Despite suggestions by current clinical guidelines that outcomes, including rate of clinical progression and mortality, are improved in patients with prostate cancer eating vegetable-rich diet, a new study has found no such correlation. The randomized, controlled Men’s Eating and Living (MEAL) study evaluated the impact of a vegetable-rich diet compared to active surveillance in 443 with stage ≤cT2a prostate cancer.
Patients in the vegetable-rich diet group reported significant increases in daily vegetable services compared to patients in the active surveillance group (P<.01), a difference that continued for 24 months. Patients in the vegetable group had a mean change of 2.01 daily total vegetable servings, compared to 0.37 daily total vegetable servings in the control group (P<.001).
Despite the increase in vegetable intake in the dietary intervention group, there were no significant differences between the two groups in either the number of patients experiencing disease progression (124 vs 121) or the time to treatment progression (HR 0.97, P = .84). The estimated 24-month progression-free survival rates were 43.5% in patients receiving dietary intervention and 41.4% in the active surveillance group.
The investigators concluded that increased consumption of vegetables does not significantly impact long-term outcomes in patients with prostate cancer. However, the authors indicated that the study may have been underpowered to identify small but meaningful differences in progression between the two groups.
Read more about this study on Medscape Medical News.